Related Experiment Video
Updated: Aug 1, 2026
Intracranial Implantation with Subsequent 3D In Vivo Bioluminescent Imaging of Murine Gliomas
Published on: November 6, 2011
Current imaging and possible therapeutic management of glucagonoma tumors: a case report
D S Johnson1, M N Coel, M Bornemann
1Department of Medicine, University of Hawaii, John A. Burns School of Medicine, Honolulu, USA.
Abstract:
Glucagonomas, like other neuroendocrine tumors, express somatostatin receptors in more than 80% of cases. Unfortunately, because of the rarity of these tumors, the sensitivity and specificity of somatostatin analog (octreotide) imaging have not been established. Nonetheless, there have been limited reports in the literature supporting the use of indium In-111 DTPA N-terminal D-phenylalanine (D-PHE1) octreotide for glucagonoma imaging and may be most beneficial as an adjuvant to conventional imaging for tumor staging and therapeutic decision making. Current therapeutic applications of octreotide focus on stabilization of disease in tumors expressing somatostatin receptors, and tumor destruction, using beta-emitting isotopes. In this report, imaging of a glucagonoma with In-111 DTPA-D-PHE1 octreotide scintigraphy is described in a 51-year-old woman examined for a large palpable abdominal mass.
Insights
Indium In-111 DTPA-D-PHE1 octreotide scintigraphy shows promise for imaging rare glucagonomas. This diagnostic tool may aid in staging and treatment decisions for neuroendocrine tumors.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- Glucagonomas are rare neuroendocrine tumors, often expressing somatostatin receptors.
- The diagnostic utility of somatostatin analogs like octreotide for glucagonoma imaging is not well-established due to tumor rarity.
Observation:
- This report details the scintigraphic imaging of a glucagonoma using indium In-111 DTPA-D-PHE1 octreotide.
- The imaging was performed on a 51-year-old female patient presenting with a large abdominal mass.
Findings:
- Indium In-111 DTPA-D-PHE1 octreotide scintigraphy demonstrated the ability to image a glucagonoma.
- The study supports the potential use of this radiotracer as an adjunct to conventional imaging.
Implications:
- This imaging modality may improve tumor staging and therapeutic decision-making for glucagonoma patients.
- Further research is warranted to establish the sensitivity and specificity of octreotide analogs in glucagonoma diagnosis.
